Literature DB >> 1845363

High prevalence of significant heart valve lesions in patients with the 'primary' antiphospholipid syndrome.

R Cervera1, M A Khamashta, J Font, P A Reyes, J L Vianna, A López-Soto, M C Amigo, R A Asherson, M Azqueta, C Paré.   

Abstract

A prospective echocardiographic study was carried out on 55 patients with the recently described 'primary' antiphospholipid syndrome derived from three university medical centres. The prevalence of valvular lesions in patients with this syndrome was 38% compared with 4% in a control group of 55 healthy volunteers (P < 0.001). Mean age of patients with valve abnormalities was 42 +/- 12 years and of those without, 30 +/- 10 years (P < 0.05). One patient had a morphologic echocardiographic pattern suggestive of non-infective verrucous mitral endocarditis. Twenty patients had a two-dimensional or Doppler echocardiographic pattern of significant valvular dysfunction--either regurgitation or stenosis--without evidence of vegetations. Mitral and aortic regurgitation were the most common lesions in these patients. During follow-up of patients with valvular disease, haemodynamically significant clinical valve disease developed in four and surgery was required in one. Eleven patients had cerebrovascular occlusions. Thus, valvular heart disease, particularly affecting the mitral and aortic valves, is common in patients with the 'primary' antiphospholipid syndrome, especially in those over 40 years old.

Entities:  

Mesh:

Year:  1991        PMID: 1845363     DOI: 10.1177/096120339100100108

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  16 in total

Review 1.  Cardiac valvulopathy in the antiphospholipid syndrome.

Authors:  Shaul Lev; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2002-12       Impact factor: 8.667

Review 2.  Treatment of the antiphospholipid syndrome.

Authors:  J C Piette; M Karmochkine; T Papo; L T Du; C Francès; B Wechsler
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

3.  Heart valve disease in systemic lupus erythematosus. Role of antiphospholipid antibodies.

Authors:  O Meyer; M Golstein; P Nicaise; C Labarre; M F Kahn
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

4.  Surgical treatment of nonbacterial thrombotic endocarditis presenting with stroke.

Authors:  A A Rabinstein; C Giovanelli; J G Romano; S Koch; A M Forteza; M Ricci
Journal:  J Neurol       Date:  2005-02-23       Impact factor: 4.849

Review 5.  The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus.

Authors:  Ozan Ünlü; Stephane Zuily; Doruk Erkan
Journal:  Eur J Rheumatol       Date:  2015-12-29

6.  Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome.

Authors:  I Krause; S Lev; A Fraser; M Blank; M Lorber; L Stojanovich; J Rovensky; J Chapman; Y Shoenfeld
Journal:  Ann Rheum Dis       Date:  2005-03-18       Impact factor: 19.103

Review 7.  [Echocardiographic functional analysis of patients with rheumatoid arthritis and collagen diseases].

Authors:  A Hagendorff; D Pfeiffer
Journal:  Z Rheumatol       Date:  2005-05       Impact factor: 1.372

Review 8.  Mitral valve surgery for mitral regurgitation caused by Libman-Sacks endocarditis: a report of four cases and a systematic review of the literature.

Authors:  Wobbe Bouma; Theo J Klinkenberg; Iwan C C van der Horst; Inez J Wijdh-den Hamer; Michiel E Erasmus; Marc Bijl; Albert J H Suurmeijer; Felix Zijlstra; Massimo A Mariani
Journal:  J Cardiothorac Surg       Date:  2010-03-23       Impact factor: 1.637

9.  Near complete resolution of nonbacterial thrombotic endocarditis in a patient with antiphospholipid antibody syndrome.

Authors:  Justin Shipman; Pradyumna Agasthi; David Majdalany; Farouk Mookadam; Reza Arsanjani
Journal:  Anatol J Cardiol       Date:  2020-08       Impact factor: 1.596

10.  Pregnancy outcome in women with antiphospholipid antibodies.

Authors:  A K al-Momen; S A Moghraby; M O el-Rab; A M Gader; S R al-Balla; A A al-Meshari; L al-Nuaim
Journal:  Clin Rheumatol       Date:  1993-09       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.